Format

Send to

Choose Destination
J Surg Oncol. 2011 Nov 1;104(6):692-8. doi: 10.1002/jso.22017. Epub 2011 Jun 28.

Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: a systematic review of survival, mortality, and morbidity.

Author information

1
Department of Surgery, University of Alberta, Edmonton, Alberta, Canada. richdeep@ualberta.ca

Abstract

Gastric cancer with peritoneal carcinomatosis has an extremely poor prognosis, which may be improved with cytoreductive surgery (CRS) combined with heated intraperitoneal chemotherapy (HIPEC). We systematically reviewed the literature regarding the efficacy of CRS + HIPEC in these patients. Electronic databases were searched from 2000 to 2010. Following CRS + HIPEC, overall median survival was 7.9 months and improved to 15 months for patients with completeness of cytoreduction scores of 0/1, however with a 30-day mortality rate of 4.8%.

PMID:
21713780
DOI:
10.1002/jso.22017
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Health
Loading ...
Support Center